利托那韦

C₃₇H₄₈N₆O₅S₂

720.94

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Ritonavir belongs to the group of protease inhibitors that are widely used in combination with other drugs in the prevention of HIV. Its mode of action involves binding to the active site of the protease enzyme and preventing the further maturation of new viral particles.

Ritonavir may be used as an analytical reference standard for the quantification of the analyte in pharmaceutical formulations using chromatography techniques.

Sales restrictions may apply.

100

pharmaceutical primary standard

BP

solid

BP

dry at room temperature

off-white

122-126  ℃

ethanol: soluble
isopropanol: soluble
methanol: soluble

1.239 g/cm³ at 20 ℃

pharmaceutical

ambient

2-8℃

1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

NCDNCNXCDXHOMX-XGKFQTDJSA-N

Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia

GHS07

Warning

H302 + H312 + H332

P280 - P301 + P312 + P330 - P302 + P352 + P312 - P304 + P340 + P312

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

11 - Combustible Solids

WGK 3